- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06313905
EVADRY® in the Treatment of Xerostomia in Sjögren's Syndrome (DRYLESS)
DRYLESS: Randomized Controlled Trial of EVADRY® vs Placebo in the Treatment of Xerostomia in Sjögren's Syndrome
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study design:
This is a randomized controlled double-blind clinical trial involving 2 groups:
- Group 1: consisting of 90 patients receiving the EVADRY dietary supplement treatment.
- Group 2: consisting of 90 patients receiving a placebo
Inclusion and exclusion criteria:
• Inclusion criteria:
The included patients meet the following criteria:
- age over 18 years
- diagnosis of Sjogren's syndrome according to ACR/EULAR 2016 criteria
- continuous xerostomia for more than 3 months
initial salivary flow rate < 0.1 ml/min
• Non-inclusion criteria:
- allergy or hypersensitivity to any of the products
- pregnancy
- breastfeeding
- oral or throat surgery before wound healing
cognitive or dementia disorders
- Exclusion criteria:
These include:
- Occurrence of cognitive or dementia disorders
- Pregnancy
- Allergy to any of the components of the EVADRY product
- Indication of oral or throat surgery
Randomization:
This is a randomization by random blocks. A co-investigator (who is not in contact with the patients) will be responsible for this randomization. The EVADRY treatment and the placebo will have the same packaging. Codes will be assigned to the sprays by the investigator responsible for the randomization. These codes will be placed in sealed envelopes and will only be opened at the end of the study. They will be kept by another investigator who has no knowledge of the randomization.
Treatment and interventions:
The EVADRY oral spray and the placebo are produced by Wellnet laboratory.
• EVADRY spray: It is a phytotherapy-based medication in the form of an oral spray. It is a 100 ml bottle containing ALEO BARBADENSIS LEAF WATER (1 ml), Chamomilla Recutita Flower extract (30 mg), TOCOPHEROL (10 mg), hyaluronic acid (2 mg), mentha spicata herb oil (10 mg), and eugenol (40 µg).
- The placebo corresponds to flavored water (mint extract) with the same taste as EVADRY. It is placed in a bottle with the same appearance as EVADRY.
Both products are administered at a rate of 5 intra-oral sprays per day.
Evaluation criteria:
• Primary evaluation criterion: It is based on the measurement of salivary flow rate (SFR). It consists of asking the patient to collect their saliva in the morning without prior stimulation (no smoking, chewing gum, or alcohol one hour before) in a graduated tube for 15 minutes. The patient should be comfortably seated with their head slightly tilted forward and their mouth open to allow saliva to flow. A value less than 0.1 ml/minute corresponds to hyposalivation.
• Secondary evaluation criteria:
- Xerostomia Inventory in French version: it is a questionnaire composed of 11 questions. For each item, there is an evaluation of its frequency (never, rarely, occasionally, quite often, very often). The total score ranges from 11 to 55 points.
- OHIP-14 questionnaire: it includes 7 dimensions with 14 items to assess quality of life. The higher the score on this questionnaire, the more negative the impact on quality of life.
- HAD scale: it is an instrument that allows screening for anxiety and depressive disorders. It consists of 14 items rated from 0 to 3 : 7 for anxiety and 7 for depression. We will have 2 scores. A score ≤7 corresponds to the absence of symptoms, ≥11 corresponds to definite symptomatology, and between the two, it is doubtful.
- Buccal Schirmer test: it consists of a strip of Whatman paper (blotting paper) placed in a polyethylene bag, with the first 5 mm of the strip protruding from one end of the bag. This end is then folded and placed under the patient's tongue in contact with the floor of the mouth for 5 minutes. The patient should be in a forward-leaning position, hands on knees, and eyes closed. After five minutes, the strip is removed and the soaked portion is measured in centimeters.
Patient follow-up:
The patients will be interviewed and examined initially. During this consultation, the patient's epidemiological and clinical data will be collected. During the same consultation, SFR and buccal Schirmer test will be measured, and Xerostomia Inventory, OHIP-14, and HAD will be calculated.
These tests will be repeated at 1, 2, and 3 months.
Interruption and end of the trial:
Patient follow-up is planned for 3 months. The statistical study is planned for 1 month.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Fatma Saïd
- Phone Number: 0021671150876
- Email: saidzribifatma@yahoo.fr
Study Contact Backup
- Name: Fatma Saïd
- Email: saidzribifatma@yahoo.fr
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- age over 18 years
- diagnosis of Sjogren's syndrome according to ACR/EULAR 2016 criteria
- continuous xerostomia for more than 3 months
- initial salivary flow rate < 0.1 ml/min
Exclusion Criteria:
- Occurrence of cognitive or dementia disorders
- Pregnancy
- Allergy to any of the components of the EVADRY product
- Indication of oral or throat surgery
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: EVADRY
90 Sjogren's syndrom patients with objective xerostomia receiving the EVADRY dietary supplement treatment.
|
The EVADRY oral spray and the placebo are produced by Wellnet laboratory. • EVADRY spray: It is a phytotherapy-based medication in the form of an oral spray. It is a 100 ml bottle containing ALEO BARBADENSIS LEAF WATER (1 ml), Chamomilla Recutita Flower extract (30 mg), TOCOPHEROL (10 mg), hyaluronic acid (2 mg), mentha spicata herb oil (10 mg), and eugenol (40 µg). |
Placebo Comparator: PLACEBO
90 Sjogren's syndrom patients with objective xerostomia receiving a placebo.
|
The placebo corresponds to flavored water (mint extract) with the same taste as EVADRY. It is placed in a bottle with the same appearance as EVADRY. Both products are administered at a rate of 5 intra-oral sprays per day. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
salivary flow rate (SFR)
Time Frame: at inclusion, after 1, 2 and 3 months
|
It consists of asking the patient to collect their saliva in the morning without prior stimulation (no smoking, chewing gum, or alcohol one hour before) in a graduated tube for 15 minutes.
The patient should be comfortably seated with their head slightly tilted forward and their mouth open to allow saliva to flow.
A value less than 0.1 ml/minute corresponds to hyposalivation.
|
at inclusion, after 1, 2 and 3 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Xerostomia Inventory in French version
Time Frame: at inclusion, after 1, 2 and 3 months
|
it is a questionnaire composed of 11 questions.
For each item, there is an evaluation of its frequency (never, rarely, occasionally, quite often, very often).
The total score ranges from 11 to 55 points
|
at inclusion, after 1, 2 and 3 months
|
Oral Health-related quality of life (OHIP-14) questionnaire
Time Frame: at inclusion, after 1, 2 and 3 months
|
it includes 7 dimensions with 14 items to assess quality of life.
The higher the score on this questionnaire, the more negative the impact on quality of life
|
at inclusion, after 1, 2 and 3 months
|
Hospital anxiety and depression (HAD) scale
Time Frame: at inclusion, after 1, 2 and 3 months
|
it is an instrument that allows screening for anxiety and depressive disorders.
It consists of 14 items rated from 0 to 3 : 7 for anxiety and 7 for depression.
We will have 2 scores.
A score ≤7 corresponds to the absence of symptoms, ≥11 corresponds to definite symptomatology, and between the two, it is doubtful
|
at inclusion, after 1, 2 and 3 months
|
Buccal Schirmer test
Time Frame: at inclusion, after 1, 2 and 3 months
|
it consists of a strip of Whatman paper (blotting paper) placed in a polyethylene bag, with the first 5 mm of the strip protruding from one end of the bag.
This end is then folded and placed under the patient's tongue in contact with the floor of the mouth for 5 minutes.
The patient should be in a forward-leaning position, hands on knees, and eyes closed.
After five minutes, the strip is removed and the soaked portion is measured in centimeters.
|
at inclusion, after 1, 2 and 3 months
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Ines Naceur, Centre Hospitalo-Universitaire La Rabta
- Study Chair: Tayssir Ben Achour, Centre Hospitalo-Universitaire La Rabta
- Study Chair: Mayssam Jridi, Centre Hospitalo-Universitaire La Rabta
- Study Director: Monia Smiti, Centre Hospitalo-Universitaire La Rabta
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Immune System Diseases
- Autoimmune Diseases
- Eye Diseases
- Disease
- Joint Diseases
- Musculoskeletal Diseases
- Rheumatic Diseases
- Connective Tissue Diseases
- Arthritis
- Stomatognathic Diseases
- Mouth Diseases
- Lacrimal Apparatus Diseases
- Arthritis, Rheumatoid
- Salivary Gland Diseases
- Dry Eye Syndromes
- Syndrome
- Sjogren's Syndrome
- Xerostomia
Other Study ID Numbers
- DRYLESS1
- CHU La Rabta (Other Identifier: La Rabta hospital)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Sjogren's Syndrome
-
The Cleveland ClinicBristol-Myers SquibbWithdrawnRheumatoid Arthritis | Inflammatory Arthritis | Primary Sjogren's Syndrome | Secondary Sjogren's SyndromeUnited States
-
RemeGen Co., Ltd.RecruitingPrimary Sjogren's SyndromeChina
-
Stanford UniversityWithdrawnPrimary Sjogren's Syndrome
-
Matthew C. BakerWithdrawnPrimary Sjogren's SyndromeUnited States
-
University College, LondonCambridge University Hospitals NHS Foundation Trust; Sheffield Teaching Hospitals... and other collaboratorsActive, not recruitingSjogren's Syndrome Childhood-onsetUnited Kingdom, Ireland
-
Keio UniversityUnknown
-
Parion SciencesCompletedXerostomia | Dry Mouth Associated With Sjogren's SyndromeUnited States
-
University Hospital MuensterNovartisCompletedPrimary Sjogren's SyndromeGermany
-
Akdeniz UniversityCompleted